Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Payables: 2022-2025

Historic Payables for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Sep 2025 value amounting to $5.8 million.

  • Day One Biopharmaceuticals' Payables rose 91.51% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.7 million, marking a year-over-year decrease of 0.87%. This contributed to the annual value of $3.3 million for FY2024, which is 26.63% up from last year.
  • As of Q3 2025, Day One Biopharmaceuticals' Payables stood at $5.8 million, which was up 13.52% from $5.1 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' 5-year Payables high stood at $15.9 million for Q4 2022, and its period low was $439,000 during Q2 2022.
  • Moreover, its 3-year median value for Payables was $4.6 million (2023), whereas its average is $4.2 million.
  • Examining YoY changes over the last 5 years, Day One Biopharmaceuticals' Payables showed a top increase of 939.86% in 2023 and a maximum decrease of 83.85% in 2023.
  • Over the past 4 years, Day One Biopharmaceuticals' Payables (Quarterly) stood at $15.9 million in 2022, then plummeted by 83.85% to $2.6 million in 2023, then climbed by 26.63% to $3.3 million in 2024, then soared by 91.51% to $5.8 million in 2025.
  • Its Payables stands at $5.8 million for Q3 2025, versus $5.1 million for Q2 2025 and $2.5 million for Q1 2025.